FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

Can Crucell deliver for J&J;?; Medicago gets FDA OK for H1N1 study;

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!



Tools

> With Dutch biotech Crucell about to be gobbled up by U.S. giant Johnson & Johnson, its chief executive Ronald Brus will need to deliver new vaccines quickly to make a success of the acquisition. Report

> Medicago has received FDA clearance for its Phase I H1N1 influenza VLP vaccine candidate clinical trial in the U.S. Medicago release

> Inovio Pharmaceuticals' new generation DNA vaccine delivery technology, which provides the powerful enabling capabilities of electroporation without contacting the skin, is highlighted in a paper published in the scientific journal Human Vaccines. Inovio release

Vaccine Market

> The BCG Vaccine Laboratory in Chennai, one of India's oldest vaccine manufacturing units, could soon become just a central drug testing lab. The Union health ministry had cancelled the manufacturing license of the company, housed in more than a century-old heritage building, Jan. 15, 2008, because it did not conform to the World Health Organization's good manufacturing protocol. News 

> Pevion Biotech today announced the appointment of Didier Hoch as Chairman of its Board of Directors. Until recently, Dr Hoch was President of Sanofi-Pasteur MSD, where he played a pivotal role in launching innovative vaccines, such as Gardasil, in Europe. Pevion release

> Vical has reported financial results for the year ended December 31, 2010. Vical had cash and investments of approximately $61 million at year-end 2010. The company received approximately $37 million of net proceeds from the sale of equity securities during 2010. Vical release


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.